BMRN FY 2025 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.2B+12.9% YoY

Gross Profit

$2.5B77.1% margin

Operating Income

$533M16.6% margin

Net Income

$349M10.8% margin

EPS (Diluted)

$1.80

Cash Flow

Operating Cash Flow

$828M

Free Cash Flow

$725M

Stock-Based Comp.

$181M

Balance Sheet

Total Assets

$7.6B

Total Liabilities

$1.5B

Stockholders' Equity

$6.1B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.2B	$2.9B	+12.9%
Gross Profit	$2.5B	$2.3B	+9.3%
Operating Income	$533M	$484M	+10.2%
Net Income	$349M	$427M	-18.3%